Deputy editor

Stus Viktor Petrovych
Scopus Author ID
https://orcid.org/0000-0002-4539-8126
ResearcherID
Doctor of Medical Sciences, Professor, Head of Urology Department, State Institution "Dnipropetrovsk Medical Academy of the Ministry of Health of Ukraine", Director of the Urology Clinic of the Public Institution "Dnipropetrovsk Regional Clinical Hospital named after I.I. Mechnikov ”, president of the Association of Urologists of the Dnipropetrovsk region.

Professor Stus is member of the dissertation council D 26.615.01 at the State Institution “Institute of Urology of the Academy of Medical Sciences of Ukraine”, member of the academic council of the State Institution “State Medical Academy of the Ministry of Health of Ukraine”, member of the regional attestation commission for surgical profile and a senior freelance specialist in Urology Department of Health of the Dnipropetrovsk Regional State Administration (since 1999), and since 2018 - an expert in the field of "Urology" at the Department of Health of the Dnipropetrovsk Regional State Administration, member of the editorial board magazine and "Medicni perspektivi" and "Health of man", deputy editor of the national magazine "Urologija", President of the Association of Urologists of Dnipropetrovsk region.

The main directions of scientific research of professor V.P. Stus - medical ecology, ecourology, assessment of the negative impact of environmental factors on the human urogenital system, methods of treating urological diseases, male infertility, chronic prostatitis and urolithiasis, erectile dysfunction.

Main scientific works:

1. Kaye K.S., Bhowmick T., Metallidis S., Stus V. et al. Effect of Meropenem-Vaborbactam vs Piperacillin-Tazobactam on Clinical Cure or Improvement and Microbial Eradication in Complicated Urinary Tract Infection: The TANGO I Randomized Clinical Trial. JAMA. 2018. Vol. 319(8). P. 788–799. doi:10.1001/jama.2018.0438.

2. Hutson T.E. et al. Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial. The Lancet Oncology. Vol. 14, Issue 13. P. 1287–1294.

3. Hutson T.E. et al. Axitinib Versus Sorafenib in First-Line Metastatic Renal Cell Carcinoma: Overall Survival From a Randomized Phase III Trial. Clinical Genitourinary Cancer. Vol. 15, Issue 1. P. 72–76.

4. Rini B.I., Plimack E.R., Stus V., Gafanov R. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N. Engl. J. Med. 2019. Vol. 380. P. 1116–1127. doi: 10.1056/NEJMoa1816714.